FDA Drug Approval Process: Complete Step-by-Step Guide From Discovery to Market
The FDA drug approval process follows a defined sequence: (1) preclinical laboratory and animal testing, (2) IND application filing, (3) Phase 1-3 clinical trials, (4) NDA or BLA submission, (5) FDA review including filing assessment, multidisciplinary review, inspections, and possible Advisory Committee, and (6) FDA action (approval or Complete Response Letter). Post-approval, the product moves into ongoing postmarket safety reporting and pharmacovigilance. Total development time varies widely by product and program.
Key Takeaways
Key Takeaways
- The FDA drug approval process follows a defined sequence from preclinical testing through post-market surveillance, but total development time varies widely by product and disease area.
- The IND goes into effect automatically 30 days after FDA receipt unless FDA places a clinical hold under 21 CFR 312.42.
- FDA's expedited programs can shorten parts of development or review for qualifying products, but they do not create a guaranteed end-to-end timeline.
- Advisory Committee votes are not binding on FDA — the agency has approved drugs with negative votes and declined drugs with positive votes.
- The FDA drug approval process is the regulatory pathway through which a pharmaceutical or biologic product demonstrates sufficient safety and efficacy to receive marketing authorization in the United States. Governed primarily by the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 USC 301 et seq.) for drugs and the Public Health Service Act (42 USC 262) for biologics, this process is among the most rigorous in the world.
- This guide walks through each step sequentially, with the regulatory citations, timelines, and practical considerations that regulatory professionals need to execute each stage.
- In this guide, you will learn:
- Every step of the FDA approval process in chronological order
- The regulatory requirements and citations for each stage
- The main regulatory requirements and milestones at each decision point
- How FDA conducts its review of NDAs and BLAs
- Post-approval requirements and ongoing obligations
- ---
Step 1: Preclinical Testing
Purpose
Preclinical testing establishes preliminary safety and biological activity of a drug candidate before it is tested in humans. This step generates the data required for an Investigational New Drug (IND) application.
Requirements
All nonclinical safety studies submitted to support an IND must comply with Good Laboratory Practice (GLP) regulations under 21 CFR Part 58. GLP requirements include:
| GLP Element | Requirement |
|---|---|
| Study director | Qualified individual responsible for study conduct |
| Quality assurance unit | Independent oversight of study compliance |
| Standard operating procedures | Written procedures for all critical activities |
| Test article characterization | Identity, purity, stability, and composition |
| Archive maintenance | Raw data preserved for study duration + retention period |
Key Preclinical Studies
Pharmacology Studies
- Primary pharmacodynamic studies (mechanism of action)
- Secondary pharmacodynamic studies (off-target effects)
- Safety pharmacology (cardiovascular, respiratory, CNS per ICH S7A and S7B)
Toxicology Studies (per ICH M3(R2))
- Single-dose acute toxicity (two species)
- Repeat-dose toxicity (rodent and non-rodent, duration supporting proposed clinical trial)
- Genotoxicity battery (in vitro bacterial mutation, in vitro chromosomal aberration, in vivo micronucleus per ICH S2(R1))
Pharmacokinetics/ADME
- Absorption, distribution, metabolism, excretion studies
- Plasma protein binding
- Metabolite identification
Planning Considerations
The time needed for preclinical work depends on the product, indication, and the scope of nonclinical studies needed to support the proposed first-in-human program.
Step 2: IND Application
Purpose
The Investigational New Drug (IND) application is the formal request to FDA for authorization to begin clinical trials in humans. Under 21 CFR 312, the IND provides FDA with the information needed to assess whether the proposed clinical investigation is safe for human subjects.
IND Content Requirements (21 CFR 312.23)
| Section | Required Content |
|---|---|
| Form FDA 1571 | Cover sheet identifying sponsor, investigators, protocol |
| Table of contents | Complete listing of all submitted sections |
| Introductory statement | Drug name, structure, pharmacological class, objectives |
| General investigational plan | Rationale, indication, approach to clinical evaluation |
| Investigator's Brochure | Compilation of all known pharmacology, toxicology, clinical data |
| Protocol(s) | Detailed Phase 1 clinical trial protocol |
| Chemistry, Manufacturing, Controls | Drug substance and product information, manufacturing process |
| Pharmacology and Toxicology | Nonclinical study reports (GLP-compliant) |
| Previous human experience | Prior clinical data, foreign marketing history (if any) |
IND Review Process
| Day | Event | Regulatory Basis |
|---|---|---|
| 0 | FDA receives IND submission | 21 CFR 312.40(a) |
| 1-30 | FDA reviews IND for safety | 21 CFR 312.40(b) |
| 30 | IND becomes effective (if no hold) | 21 CFR 312.40(b)(1) |
The IND does not receive formal "approval." It goes into effect automatically 30 calendar days after FDA receipt unless FDA places a clinical hold.
Clinical Hold
If FDA identifies safety concerns, it may place a full or partial clinical hold under 21 CFR 312.42:
| Hold Type | Effect | FDA Must Respond Within |
|---|---|---|
| Full clinical hold | All clinical work under IND must stop | 30 days (written explanation) |
| Partial clinical hold | Specific trial or activity suspended | 30 days (written explanation) |
To lift a clinical hold, the sponsor must address all deficiencies identified in FDA's hold letter and submit a complete response under 21 CFR 312.42(e).
Step 3: Phase 1 Clinical Trials
Purpose
Phase 1 trials are the first human studies, primarily designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. They are defined under 21 CFR 312.21(a).
Study Design
| Parameter | Typical Phase 1 |
|---|---|
| Subjects | 20-80 healthy volunteers (patients for oncology/rare disease) |
| Primary objective | Safety and tolerability |
| Secondary objectives | PK, PD, maximum tolerated dose |
| Common designs | Single ascending dose (SAD), multiple ascending dose (MAD), food effect, drug-drug interaction |
| Duration | Several weeks to months per study; 6-18 months for Phase 1 program |
| Sites | Often single-center, Phase 1 clinical pharmacology units |
Regulatory Requirements During Phase 1
| Requirement | Regulation |
|---|---|
| Informed consent | 21 CFR 50 |
| IRB review and approval | 21 CFR 56 |
| IND safety reporting (serious AEs) | 21 CFR 312.32 |
| IND annual report | 21 CFR 312.33 |
| GCP compliance | 21 CFR 312, ICH E6(R2) |
| Protocol amendments | 21 CFR 312.30 |
Step 4: Phase 2 Clinical Trials
Purpose
Phase 2 trials provide preliminary evidence of efficacy in the target patient population and further characterize safety. Defined under 21 CFR 312.21(b), these studies are dose-finding and proof-of-concept investigations.
Study Design
| Parameter | Typical Phase 2 |
|---|---|
| Subjects | 100-500 patients with target condition |
| Primary objective | Preliminary efficacy and dose-response |
| Secondary objectives | Safety in patients, biomarker correlation |
| Common designs | Randomized, controlled, dose-ranging |
| Duration | 1-3 years |
| Sites | Multi-center, often 10-50 sites |
Phase 2a vs Phase 2b
| Sub-phase | Focus | Typical Size |
|---|---|---|
| Phase 2a | Proof of concept (does it work?) | 50-150 patients |
| Phase 2b | Dose finding (what dose works best?) | 100-300 patients |
End-of-Phase 2 Meeting
The End-of-Phase 2 (EOP2) meeting with FDA is one of the most strategically important interactions in drug development. This Type B meeting (per FDA Guidance on Formal Meetings, December 2023) addresses:
- Adequacy of Phase 2 data to support Phase 3
- Phase 3 trial design (endpoints, population, comparator, statistical plan)
- Regulatory pathway considerations (standard vs expedited programs)
- CMC development plan for commercial-scale manufacturing
- Proposed labeling and indication
The EOP2 meeting is often the point at which sponsors confirm whether the available data are adequate to support pivotal trial planning.
Step 5: Phase 3 Clinical Trials
Purpose
Phase 3 trials are the pivotal, confirmatory studies that generate the primary evidence for NDA/BLA submission. Defined under 21 CFR 312.21(c), these studies must demonstrate substantial evidence of effectiveness and adequate safety in a larger patient population.
Study Design
| Parameter | Typical Phase 3 |
|---|---|
| Subjects | 300-3,000+ patients (sometimes 10,000+ for outcomes studies) |
| Primary objective | Confirm efficacy on clinical or validated surrogate endpoint |
| Secondary objectives | Comprehensive safety characterization, subgroup analyses |
| Common designs | Randomized, double-blind, active or placebo controlled |
| Duration | 2-4 years (longer for cardiovascular outcomes trials) |
| Sites | Multi-center, often 50-200+ global sites |
| Requirement | Usually two adequate and well-controlled studies (21 CFR 314.126) |
Evidentiary Standard
21 CFR 314.126 defines the characteristics of adequate and well-controlled studies:
- Clear statement of objectives
- Comparison with a control (placebo, active control, dose-comparison, no treatment, historical control)
- Method of subject selection ensuring comparability of treatment groups
- Method to minimize bias (randomization, blinding)
- Adequate assessment of response
FDA's Guidance, "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products" (May 1998), discusses when a single adequate and well-controlled study may suffice for approval, including when:
- The study is large and multicenter
- Results are statistically very persuasive
- A related endpoint also shows benefit
- The disease is serious with unmet need
Step 6: NDA/BLA Preparation and Submission
Pre-Submission Activities
| Activity | Timing Before Submission | Purpose |
|---|---|---|
| Pre-NDA/Pre-BLA meeting | 6-12 months | Align with FDA on submission content and approach |
| Clinical study reports | 4-8 months | Finalize per ICH E3 format |
| Integrated summaries | 4-6 months | ISS (safety) and ISE (efficacy) |
| Module 2 summaries | 4-8 months | Quality Overall Summary, Clinical Overview/Summary |
| eCTD compilation | 3-6 months | Assemble and validate per ICH M8 |
| Safety update report | 2-4 months | 120-day safety update (21 CFR 314.50(d)(5)(vi)(b)) |
NDA Content (21 CFR 314.50)
| Module | Content |
|---|---|
| Module 1 | FDA forms (1571, 356h), cover letter, patent information (Form 3542), proposed labeling, financial certification, environmental assessment or claim for exclusion |
| Module 2 | Quality Overall Summary (2.3), Nonclinical Overview (2.4), Clinical Overview (2.5), Nonclinical Tabulated Summary (2.6), Clinical Summary (2.7) |
| Module 3 | Drug substance (3.2.S), drug product (3.2.P), appendices (3.2.A), regional information (3.2.R) |
| Module 4 | Pharmacology, pharmacokinetics, toxicology study reports |
| Module 5 | Clinical pharmacology, efficacy, and safety study reports; literature references |
BLA Content (21 CFR 601.2)
BLAs follow the same eCTD Module 1-5 structure but with additional requirements specific to biological products:
- Facility information for each manufacturing site
- Environmental impact analysis
- Samples of the product (if requested)
- Labeling including container labels
Submission Requirements
| Requirement | Details |
|---|---|
| Format | eCTD (electronic Common Technical Document) per ICH M8 |
| Gateway | FDA Electronic Submissions Gateway (ESG) |
| User fee | PDUFA fee (Section 736(a) of FD&C Act) paid within 20 days |
| Pre-submission | eCTD validation prior to gateway submission |
Step 7: FDA Filing Review (Days 1-60)
The 60-Day Filing Review
After receiving the NDA/BLA, FDA conducts a 60-day filing review under 21 CFR 314.101 to determine whether the application is complete enough for substantive review.
Filing Review Assessment
| Criterion | What FDA Evaluates |
|---|---|
| Completeness | All required sections and data present |
| Regulatory basis | Appropriate application type (505(b)(1), 505(b)(2), 351(a)) |
| Technical adequacy | Studies are adequate and well-controlled |
| Format compliance | eCTD structure and formatting correct |
| User fee | PDUFA fee paid |
Filing Outcomes
| Outcome | Effect |
|---|---|
| Filed | Application accepted for review; PDUFA date assigned where applicable |
| Refuse to File (RTF) | Application incomplete; returned to sponsor |
| Filed with deficiencies | Accepted but issues flagged for resolution |
Common RTF issues include missing required components, major data gaps, or serious format and submission defects.
Step 8: FDA Primary Review (Months 2-8)
Multidisciplinary Review
Upon filing, FDA assigns a review team composed of specialists across multiple disciplines:
| Reviewer | Focus Area | Key Assessments |
|---|---|---|
| Medical officer | Clinical efficacy and safety | Benefit-risk assessment, labeling |
| Pharmacology reviewer | Nonclinical pharmacology and toxicology | Animal study adequacy, toxicity signals |
| Chemistry reviewer | CMC (Module 3) | Manufacturing, specifications, stability |
| Statistical reviewer | Clinical trial statistics | Study design, analyses, conclusions |
| Clinical pharmacology | PK/PD, drug interactions | Dosing recommendations, populations |
| Biopharmaceutics reviewer | Bioavailability, dissolution | Formulation performance |
| Microbiology reviewer | Anti-infective drugs only | Susceptibility, resistance |
Mid-Cycle Communication
Under PDUFA VII, FDA commits to a mid-cycle communication for standard review applications (approximately month 5-6) and earlier for priority review. This communication:
- Identifies outstanding issues
- Summarizes review progress
- Highlights potential concerns that could affect the action date
- Provides an opportunity for sponsor response
Labeling Negotiations
FDA and the sponsor negotiate the United States Prescribing Information (USPI, or "PI") throughout the review:
| Labeling Component | Content | Regulatory Basis |
|---|---|---|
| Highlights | Summary of essential information | 21 CFR 201.57(a) |
| Full Prescribing Information | Complete product information | 21 CFR 201.57(c) |
| Patient labeling | Medication Guide or PPI (if required) | 21 CFR 208 |
| Indications and Usage | Approved therapeutic use | 21 CFR 201.57(c)(2) |
| Dosage and Administration | Recommended dosing | 21 CFR 201.57(c)(3) |
| Warnings and Precautions | Safety information | 21 CFR 201.57(c)(6) |
| Adverse Reactions | Clinical trial and post-market AEs | 21 CFR 201.57(c)(7) |
| Boxed Warning | Most serious safety concerns | 21 CFR 201.57(c)(1) |
Step 9: Inspections
GMP Manufacturing Inspection
FDA inspects manufacturing facilities under 21 CFR Parts 210 and 211 to verify compliance with current Good Manufacturing Practice (cGMP). Pre-approval inspections (PAIs) are conducted for:
- Drug substance manufacturing sites
- Drug product manufacturing sites
- Key testing laboratories
- Contract manufacturers
| Inspection Focus | What FDA Assesses |
|---|---|
| Facility and equipment | Suitability, cleanliness, maintenance |
| Production records | Batch records match NDA/BLA commitments |
| Quality systems | SOPs, deviations, CAPA, change control |
| Laboratory controls | Testing methods, data integrity |
| Validation | Process validation, cleaning validation |
| Data integrity | 21 CFR Part 11 compliance, audit trails |
GCP Clinical Site Inspection
FDA's Office of Scientific Investigations (OSI) may inspect clinical trial sites to verify:
- Data integrity and accuracy
- Informed consent compliance (21 CFR Part 50)
- IRB oversight (21 CFR Part 56)
- Protocol adherence
- Investigator qualifications
Inspection Outcomes
| Classification | Meaning | Impact on NDA/BLA |
|---|---|---|
| NAI (No Action Indicated) | No significant deviations | No impact |
| VAI (Voluntary Action Indicated) | Minor deviations, corrective action recommended | Usually no impact |
| OAI (Official Action Indicated) | Significant violations; FDA Form 483 + Warning Letter | May delay or prevent approval |
Step 10: Advisory Committee Meeting
When Advisory Committees Convene
FDA is not required to convene an Advisory Committee (AdCom) for every application. Under 21 CFR Part 14, Advisory Committee meetings are typically held for:
- First-in-class drugs
- Drugs with novel mechanisms of action
- Applications with complex benefit-risk considerations
- Drugs with significant safety concerns
- NMEs for serious conditions where FDA seeks external input
Advisory Committee Process
| Step | Timing | Details |
|---|---|---|
| FDA announces meeting | ~60 days before | Federal Register notice |
| Briefing documents posted | ~3-4 days before | FDA and sponsor documents published |
| Public hearing | Meeting day | Open to public comment |
| Committee discussion | Meeting day | Scientific review of evidence |
| Vote | Meeting day | Committee votes on specific questions |
| FDA decision | After meeting | FDA considers but is not bound by vote |
“Key Point: Advisory Committee votes are not binding on FDA. FDA considers the committee's advice along with the full administrative record.
Step 11: FDA Action (PDUFA Date)
Possible Actions
On or before the PDUFA date, FDA takes one of the following actions:
Approval Letter
FDA issues an Approval Letter under 21 CFR 314.105 (NDA) or 21 CFR 601.4 (BLA), authorizing the sponsor to market the drug for the approved indication(s). The approval letter specifies:
- Approved indication and population
- Final labeling
- Post-marketing requirements (PMRs)
- Post-marketing commitments (PMCs)
- REMS requirements (if applicable)
- Effective date of approval
Complete Response Letter (CRL)
Under 21 CFR 314.110, FDA issues a CRL when it identifies deficiencies that prevent approval. The CRL:
- Describes all deficiencies identified during review
- Does not approve or reject the application
- Requires sponsor action to address deficiencies
- Sponsor may resubmit (Class 1 or Class 2), request hearing, or withdraw
Extension (Major Amendment)
If FDA requests significant additional information that cannot be evaluated within the current review period, the PDUFA date may be extended by 3 months from the date FDA receives the sponsor's response.
Step 12: Post-Market Surveillance (Ongoing)
Post-Approval Obligations
After approval, the sponsor assumes ongoing regulatory obligations:
| Obligation | Regulatory Basis | Timing |
|---|---|---|
| Adverse event reporting | 21 CFR 314.80 (NDA) / 21 CFR 600.80 (BLA) | 15 days (serious), periodic |
| Annual reports | 21 CFR 314.81(b)(2) | Within 60 days of NDA anniversary |
| Post-marketing studies (PMR) | FD&C Act 505(o)(3) | Per FDA-specified schedule |
| Post-marketing commitments (PMC) | Negotiated with FDA | Per agreed schedule |
| REMS compliance | FD&C Act 505-1 | Duration of marketing |
| Labeling updates | 21 CFR 314.70 | As new safety information emerges |
| Manufacturing changes | 21 CFR 314.70 | Supplement or annual report per change category |
| Drug listing | 21 CFR 207 | Quarterly updates |
Phase 4 Studies
Phase 4 (post-marketing) studies may be required or committed to at approval:
| Type | Purpose | Typical Duration |
|---|---|---|
| PMR safety study | Evaluate specific safety signal | 2-5 years |
| Confirmatory efficacy study | Verify clinical benefit (accelerated approval) | 2-7 years |
| Pediatric study | Assess use in pediatric population (PREA) | 2-5 years |
| REMS assessment | Evaluate REMS effectiveness | Per REMS schedule |
Complete Process Summary
| Step | Duration | Regulatory Filing/Decision |
|---|---|---|
| 1. Preclinical testing | 3-6 years | GLP compliance (21 CFR 58) |
| 2. IND application | 30 days review | IND effective or clinical hold (21 CFR 312) |
| 3. Phase 1 trials | 1-2 years | Protocol under IND (21 CFR 312.21(a)) |
| 4. Phase 2 trials | 2-3 years | EOP2 meeting (FDA Guidance) |
| 5. Phase 3 trials | 2-4 years | Pivotal studies (21 CFR 312.21(c)) |
| 6. NDA/BLA submission | 3-6 months prep | 21 CFR 314.50 / 21 CFR 601.2 |
| 7. Filing review | 60 days | File or RTF (21 CFR 314.101) |
| 8. FDA review | 6-10 months | PDUFA VII commitment |
| 9. Inspections | During review | 21 CFR 211 (GMP) / ICH E6 (GCP) |
| 10. Advisory Committee | If convened | 21 CFR Part 14 |
| 11. FDA action | PDUFA date | Approval (314.105) or CRL (314.110) |
| 12. Post-market | Ongoing | 21 CFR 314.80, 314.81 |
Total development time varies substantially. For filed NDAs and BLAs subject to PDUFA goals, the review portion typically includes the filing review period plus the applicable standard or priority review goal.
Key Regulatory References
| Reference | Citation |
|---|---|
| Federal Food, Drug, and Cosmetic Act | 21 USC 301 et seq. |
| Public Health Service Act | 42 USC 262 |
| IND Regulations | 21 CFR Part 312 |
| NDA Regulations | 21 CFR Part 314 |
| BLA Regulations | 21 CFR Part 601 |
| GLP Regulations | 21 CFR Part 58 |
| cGMP Regulations | 21 CFR Parts 210, 211 |
| Informed Consent | 21 CFR Part 50 |
| IRB Regulations | 21 CFR Part 56 |
| Advisory Committees | 21 CFR Part 14 |
| Electronic Records | 21 CFR Part 11 |
| Drug Labeling | 21 CFR 201.57 |
| Adverse Event Reporting | 21 CFR 314.80 |
| ICH M3(R2) | Nonclinical Safety Studies |
| ICH E3 | Clinical Study Reports |
| ICH E6(R2) | Good Clinical Practice |
| ICH M4 | Common Technical Document |
| ICH M8 | eCTD Specification |
| PDUFA VII Commitment Letter | FDA, September 2022 |
| Expedited Programs Guidance | FDA, 2014 |
| Formal Meetings Guidance | FDA, December 2023 |
References
Sources
- Federal Food, Drug, and Cosmetic Act | FDA
- 42 U.S.C. 262 | Legal Information Institute
- 21 CFR Part 312 | eCFR
- 21 CFR Part 314 | eCFR
- 21 CFR Part 601 | eCFR
- 21 CFR Part 58 | eCFR
- 21 CFR Parts 210 and 211 | eCFR
- Expedited Programs for Serious Conditions: Drugs and Biologics | FDA
- Prescription Drug User Fee Amendments | FDA
- ICH Guidelines